Name: Atebrioz (zilurgisertib) in Fibrodysplasia ossificans progressiva: Cost assumptions
Published: 2026-09-27T12:28:00-04:00

Economic information and modeling report Budget impact model

Cost assumptions

3 evidence topics · 2 sources

Zilurgisertib: list price not announced as of 28 September 2026

“Mirum, which predicted peak sales of more than $200 million earlier this year for Atebrioz, has not yet revealed a list price and will announce the cost when it becomes available in October, Peetz said.” (opens the source at this quote in a new tab)

Palovarotene budget impact analysis submitted to CADTH: drug and standard-of-care costs

“The sponsor’s analysis included drug acquisition costs for palovarotene based on the sponsor’s submitted price. SoC was assumed by the sponsor to comprise nonsteroidal anti-inflammatory drugs, corticosteroids, and COX-2 inhibitors, and no costs for SoC were included in the model.” (opens the source at this quote in a new tab)
“The annual estimated cost of palovarotene estimated by the sponsor (8 to 14 years: $767,812; 15 to 24 years: $1,163,606; ≥ 25 years: $863,087) was based on the chronic regimen and flare-up regimens and incorporated the estimated annual number of flares per year for each age group based on the MOVE trial.” (opens the source at this quote in a new tab)
“Finally, in the BIA, the sponsor assumed an equal distribution of patients across 3 age groups, in the calculation of the estimated annual per-patient acquisition cost of $869,401 for palovarotene.” (opens the source at this quote in a new tab)

Palovarotene: cost of flare-up dosing

“CADTH estimates that the cost associated with treating a 12-week flare-up ranges from approximately $181,563 to $363,126 per patient, depending on patient age and weight.” (opens the source at this quote in a new tab)
“Costs related to persistent flare-ups or new flare-ups during the course of a flare-up regimen are not captured within the sponsor’s BIA.” (opens the source at this quote in a new tab)